Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 17/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686820 | 0.85 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497285 | 0.82 | ADORA2B (0.65) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1497231 | 0.81 | ADORA2B (0.69) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL9885711 | 0.81 | ADORA2B (0.58) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL9885718 | 0.80 | ADORA2B (0.55) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1497264 | 0.80 | ADORA2B (0.67) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL27865790 | 0.79 | ADORA2B (0.57) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1243117 | 0.79 | ADORA2B (0.58) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1497142 | 0.78 | ADORA2B (0.60) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL7220779 | 0.78 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.